TGFB1 and breast carcinoma: In associated studies in mice with EMT6 breast cancer tumours, which display an immune-excluded phenotype, treatment with either TGFβ or PD-L1 blocking therapy had a minimal effect, but combination treatment led to increased tumour infiltrating T-cells and tumour regression.